US4458066A
(en)
|
1980-02-29 |
1984-07-03 |
University Patents, Inc. |
Process for preparing polynucleotides
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
EP0154316B1
(fr)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Lymphokine chimiquement modifiée et son procédé de préparation
|
US4978672A
(en)
|
1986-03-07 |
1990-12-18 |
Ciba-Geigy Corporation |
Alpha-heterocyclc substituted tolunitriles
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
EP0307434B2
(fr)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Anticorps alteres
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
DE3856559T2
(de)
|
1987-05-21 |
2004-04-29 |
Micromet Ag |
Multifunktionelle Proteine mit vorbestimmter Zielsetzung
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
ATE95193T1
(de)
|
1987-06-17 |
1993-10-15 |
Sandoz Ag |
Cyclosporine und deren benutzung als arzneimittel.
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
DE68925966T2
(de)
|
1988-12-22 |
1996-08-29 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
FR2650598B1
(fr)
|
1989-08-03 |
1994-06-03 |
Rhone Poulenc Sante |
Derives de l'albumine a fonction therapeutique
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
WO1991006570A1
(fr)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
MOLECULES RECEPTRICES Fc HYBRIDES
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
WO1992010591A1
(fr)
|
1990-12-14 |
1992-06-25 |
Cell Genesys, Inc. |
Chaines chimeriques utilisees comme voies de transduction de signal associe a un recepteur
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
WO1994004679A1
(fr)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Procede pour fabriquer des anticorps humanises
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
FR2686901A1
(fr)
|
1992-01-31 |
1993-08-06 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
ES2149768T3
(es)
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
CA2118508A1
(fr)
|
1992-04-24 |
1993-11-11 |
Elizabeth S. Ward |
Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes
|
EP1621554B2
(fr)
|
1992-08-21 |
2012-08-29 |
Vrije Universiteit Brussel |
Immunoglobulines dépourvus de chaînes légères
|
ATE348110T1
(de)
|
1992-10-28 |
2007-01-15 |
Genentech Inc |
Hvegf rezeptor als vegf antagonist
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
CN1117155C
(zh)
|
1994-07-29 |
2003-08-06 |
史密丝克莱恩比彻姆有限公司 |
新型化合物
|
WO2000073452A2
(fr)
|
1999-06-02 |
2000-12-07 |
Genentech, Inc. |
Compositions et methodes de traitement de maladies liees a l'immunite
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
DE69731289D1
(de)
|
1996-03-18 |
2004-11-25 |
Univ Texas |
Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
|
MY129541A
(en)
|
1996-06-25 |
2007-04-30 |
Novartis Ag |
Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
|
AU4055697A
(en)
|
1996-08-16 |
1998-03-06 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
WO1998023289A1
(fr)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
Modulation de la fixation de l'igg au fcrn
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
KR100794454B1
(ko)
|
1997-04-07 |
2008-01-16 |
제넨테크, 인크. |
항-vegf 항체
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
US6689607B2
(en)
|
1997-10-21 |
2004-02-10 |
Human Genome Sciences, Inc. |
Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
US6503184B1
(en)
|
1997-10-21 |
2003-01-07 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
|
JP2001520039A
(ja)
|
1997-10-21 |
2001-10-30 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
|
AU2591599A
(en)
|
1998-02-09 |
1999-08-23 |
Genentech Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
AU3545399A
(en)
|
1998-04-08 |
1999-10-25 |
G.D. Searle & Co. |
Dual avb3 and metastasis-associated receptor ligands
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
EP1095142A2
(fr)
|
1998-07-22 |
2001-05-02 |
Incyte Pharmaceuticals, Inc. |
Molecules associees a une proliferation cellulaire
|
AU3449899A
(en)
|
1998-08-13 |
2000-03-06 |
G.D. Searle & Co. |
Multivalent avb3 and Metastasis-Associated Receptor Ligands
|
JP2002531092A
(ja)
|
1998-12-01 |
2002-09-24 |
ジェネンテック・インコーポレーテッド |
腫瘍性細胞成長阻害のための組成物及び方法
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
EP2364997A3
(fr)
|
1999-01-15 |
2012-07-04 |
Genentech, Inc. |
Variantes de polypeptide et fonction effectrice altérée
|
JP2004516227A
(ja)
|
1999-03-08 |
2004-06-03 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患を治療するための組成物と方法
|
KR20010104373A
(ko)
|
1999-03-08 |
2001-11-24 |
제넨테크, 인크. |
혈관신생 및 심혈관형성의 촉진 또는 억제 방법
|
AU2600800A
(en)
|
1999-03-08 |
2000-09-28 |
Genentech Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization
|
ES2420835T3
(es)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedimiento para controlar la actividad de las moléculas inmunofuncionales
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
PT1196186E
(pt)
|
1999-07-12 |
2008-02-14 |
Genentech Inc |
Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
|
DE19932688B4
(de)
|
1999-07-13 |
2009-10-08 |
Scil Proteins Gmbh |
Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
AU4314801A
(en)
|
2000-02-11 |
2001-08-20 |
Lexigen Pharm Corp |
Enhancing the circulating half-life of antibody-based fusion proteins
|
CA2747325A1
(fr)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Proteines fusionnees a l'albumine
|
EP1328626B1
(fr)
|
2000-05-26 |
2013-04-17 |
National Research Council Of Canada |
Anticorps cibles sur le cerveau a domaine unique, derives d'anticorps de lama
|
US20020076406A1
(en)
|
2000-07-25 |
2002-06-20 |
Leung Shui-On |
Multivalent target binding protein
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
CN1308447C
(zh)
|
2000-10-20 |
2007-04-04 |
中外制药株式会社 |
低分子化的激动剂抗体
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
US20030133936A1
(en)
|
2001-07-12 |
2003-07-17 |
Byrne Michael Chapman |
CD25markers and uses thereof
|
JP2005532253A
(ja)
|
2001-10-25 |
2005-10-27 |
ジェネンテック・インコーポレーテッド |
糖タンパク質組成物
|
PT1441737E
(pt)
|
2001-10-30 |
2006-12-29 |
Dana Farber Cancer Inst Inc |
Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
|
EP1478648B1
(fr)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Composes contenant du phosphore et utilisations associees
|
DOP2003000613A
(es)
|
2002-03-13 |
2003-09-30 |
Array Biopharma Inc |
Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
|
US7495090B2
(en)
|
2002-05-23 |
2009-02-24 |
The Regents Of The University Of California |
Nucleic acids encoding chimeric CD154 polypeptides
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
JP4727992B2
(ja)
|
2002-11-15 |
2011-07-20 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
癌転移および癌転移に伴なう骨量減少を予防および処置するための方法
|
JP2006515750A
(ja)
|
2002-12-20 |
2006-06-08 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多価リンホトキシンβレセプターアゴニストおよびそれを使用する治療
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
EP2572715A1
(fr)
|
2002-12-30 |
2013-03-27 |
3M Innovative Properties Company |
Combinaisons immunostimulantes
|
KR101166749B1
(ko)
|
2003-02-11 |
2012-07-27 |
베르날리스(캠브리지)리미티드 |
열쇼크 단백질 저해제로서의 이소옥사졸 화합물
|
WO2004072266A2
(fr)
|
2003-02-13 |
2004-08-26 |
Kalobios Inc. |
Ingenierie de l'affinite des anticorps par un remplacement complementaire en serie guide par epitope
|
EP1462114A1
(fr)
|
2003-03-28 |
2004-09-29 |
Universiteit Utrecht Holding B.V. |
Procédés et moyens pour opprimer les symptomes d'une maladie allergique par inhibition du récepteur du facteur de nécrose tumorale inductible par les glucocorticoides (GRIT ou TNFRSF18)
|
CN1809589A
(zh)
*
|
2003-05-23 |
2006-07-26 |
Wyeth公司 |
Gitr配体和gitr配体相关分子和抗体及其应用
|
KR20060052681A
(ko)
|
2003-05-23 |
2006-05-19 |
와이어쓰 |
Gitr 리간드, gitr 리간드-연관 분자, 항체 및그의 용도
|
DE10324447A1
(de)
|
2003-05-28 |
2004-12-30 |
Scil Proteins Gmbh |
Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
|
UA101945C2
(uk)
|
2003-05-30 |
2013-05-27 |
Дженентек, Инк. |
Лікування злоякісного новоутворення за допомогою бевацизумабу
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP1660126A1
(fr)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonistes ou antagonistes du recepteur du facteur de necrose tumorale induit par les glucocorticoides (gitr) ou de son ligand utilises dans le traitement des troubles immuns, des infections et du cancer
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
WO2005044853A2
(fr)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anticorps anti-vegf
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
JP2007509185A
(ja)
|
2003-10-27 |
2007-04-12 |
ノバルティス アクチエンゲゼルシャフト |
βアミロイド産生および/または凝集と関係がある神経障害および血管障害の処置のためのインドリル−ピロールジオン誘導体
|
WO2005055808A2
(fr)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions et methodes pour le diagnostic et le traitement du cancer du poumon
|
HUE026132T2
(en)
|
2004-01-07 |
2016-05-30 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specific monoclonal antibody and its uses
|
JP4782700B2
(ja)
|
2004-01-20 |
2011-09-28 |
カロバイオス ファーマシューティカルズ インコーポレイティッド |
最低限必須な結合決定基を用いた抗体特異性の移入
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
KR20060132006A
(ko)
|
2004-03-23 |
2006-12-20 |
비오겐 아이덱 엠에이 아이엔씨. |
수용체 커플링제 및 이의 치료적 용도
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
EP3943494A1
(fr)
|
2004-05-13 |
2022-01-26 |
Icos Corporation |
Quinazolinones utilisées en tant qu'inhibiteurs de la phosphatidylinositol 3-kinase delta humaine
|
WO2006083289A2
(fr)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
GB0417487D0
(en)
|
2004-08-05 |
2004-09-08 |
Novartis Ag |
Organic compound
|
US20060099171A1
(en)
|
2004-11-05 |
2006-05-11 |
Masahide Tone |
Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
|
AU2005306502B2
(en)
|
2004-11-16 |
2012-11-15 |
Humanigen, Inc. |
Immunoglobulin variable region cassette exchange
|
WO2006074399A2
(fr)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Molecules de liaison multispecifiques comprenant des peptides de connexion
|
AU2006213875B2
(en)
|
2005-02-08 |
2010-08-19 |
Genzyme Corporation |
Antibodies to TGFBETA
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
EP1885396A2
(fr)
|
2005-05-04 |
2008-02-13 |
Quark Pharmaceuticals, Inc. |
Anticorps recombinants diriges contre cd55 et cd59 et leur utilisation
|
AU2006244497B2
(en)
|
2005-05-06 |
2011-09-22 |
Providence Health & Services - Oregon |
Trimeric OX40L-immunoglobulin fusion protein and methods of use
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
JP4984160B2
(ja)
|
2005-06-07 |
2012-07-25 |
国立大学法人 東京大学 |
抗体の作製方法
|
DK1907424T3
(en)
|
2005-07-01 |
2015-11-09 |
Squibb & Sons Llc |
HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
|
US8211648B2
(en)
|
2005-07-22 |
2012-07-03 |
Kalobios Pharmaceuticals, Inc. |
Secretion of antibodies without signal peptides from bacteria
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
PE20070427A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
|
WO2007044887A2
(fr)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Procede de production d'une population homogene d'anticorps bispecifiques tetravalents
|
EP1777294A1
(fr)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
|
AR056142A1
(es)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
TWI531652B
(zh)
|
2005-12-02 |
2016-05-01 |
美國紐約大學西奈山醫學院 |
表現非原生表面蛋白質之嵌合病毒及其用途
|
ES2700433T3
(es)
|
2005-12-13 |
2019-02-15 |
Incyte Holdings Corp |
Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus
|
EP2347775B1
(fr)
|
2005-12-13 |
2020-04-15 |
President and Fellows of Harvard College |
Echafaudages pour transplantation cellulaire
|
SI1963368T1
(sl)
|
2005-12-13 |
2012-11-30 |
Lilly Co Eli |
Anti il protitelesa
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
CN103073639A
(zh)
|
2006-03-17 |
2013-05-01 |
比奥根艾迪克Ma公司 |
稳定的多肽组合物
|
KR101464385B1
(ko)
|
2006-04-19 |
2014-11-21 |
노파르티스 아게 |
6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
CA2654317A1
(fr)
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur
|
PE20110220A1
(es)
|
2006-08-02 |
2011-04-11 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
WO2008073160A2
(fr)
|
2006-08-17 |
2008-06-19 |
The Trustees Of Columbia University In The City Of New York |
Procédés de conversion ou d'induction d'une immunité protectrice
|
TWI454480B
(zh)
|
2006-08-18 |
2014-10-01 |
Novartis Ag |
催乳激素受體(prlr)之專一性抗體及其用途
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
WO2008064157A1
(fr)
|
2006-11-22 |
2008-05-29 |
Incyte Corporation |
Imidazotriazines et imidazopyrimidines utilisées en tant qu'inhibiteurs de kinases
|
US20080318886A1
(en)
|
2006-12-05 |
2008-12-25 |
Prussak Charles E |
Methods of Increasing Cancer Sensitivity to Chemotherapeutic Agents Using Chimeric ISF35
|
KR101149295B1
(ko)
|
2006-12-08 |
2012-07-05 |
아이알엠 엘엘씨 |
단백질 키나제 억제제로서의 화합물
|
WO2008140621A2
(fr)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Virus oncolytiques transgéniques et leurs utilisations
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用
|
ES2437327T3
(es)
|
2007-06-18 |
2014-01-10 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor PD-1 humano de muerte programada
|
WO2009002401A2
(fr)
|
2007-06-21 |
2008-12-31 |
President And Fellows Of Harvard College |
Échafaudages pour recueil ou élimination de cellules
|
JP2010531878A
(ja)
|
2007-06-27 |
2010-09-30 |
マリン ポリマー テクノロジーズ,インコーポレーテッド |
IL‐15とIL‐15Rαとの複合体及びその使用
|
ES2591281T3
(es)
*
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
JP2010535032A
(ja)
|
2007-07-31 |
2010-11-18 |
メディミューン,エルエルシー |
多重特異性エピトープ結合性タンパク質およびその用途
|
JP2010538012A
(ja)
|
2007-08-28 |
2010-12-09 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
Igf−1rの複数のエピトープに結合する組成物
|
US20090155255A1
(en)
|
2007-09-27 |
2009-06-18 |
Biogen Idec Ma Inc. |
Cd23 binding molecules and methods of use thereof
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8747847B2
(en)
|
2008-02-11 |
2014-06-10 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
JP5690143B2
(ja)
|
2008-02-13 |
2015-03-25 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
持続的細胞プログラミング装置
|
EP2262837A4
(fr)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Protéines de liaison avec pd-1
|
WO2009114870A2
(fr)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Inhibiteurs de kinases, et procédés d’utilisation associés
|
AR070924A1
(es)
|
2008-03-19 |
2010-05-12 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
|
JP5522405B2
(ja)
|
2008-04-25 |
2014-06-18 |
協和発酵キリン株式会社 |
安定な多価抗体
|
EP3287449A3
(fr)
|
2008-05-21 |
2018-05-30 |
Incyte Holdings Corporation |
Sels de 2-fluoro-n-méthyl-4-[7-(quinolin-6-yl-méthyl) - imidazo [1,2-b] [1,2,4] triazin-2-yl] benzamide et procédés associés à leur préparation
|
KR101257158B1
(ko)
|
2008-05-23 |
2013-04-23 |
노파르티스 아게 |
단백질 티로신 키나제 억제제로서의 퀴놀린 및 퀴녹살린의 유도체
|
PE20100087A1
(es)
|
2008-06-25 |
2010-02-08 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
US20110177070A1
(en)
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
CA2730106A1
(fr)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Inhibiteurs de kinases et procedes d'utilisation
|
SI2315780T1
(sl)
|
2008-07-17 |
2015-11-30 |
Novartis Ag |
Sestavki in postopki uporabe za terapevtska protitelesa
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
EP2331547B1
(fr)
|
2008-08-22 |
2014-07-30 |
Novartis AG |
Composés de pyrrolopyrimidine et leurs utilisations
|
PE20110435A1
(es)
|
2008-08-25 |
2011-07-20 |
Amplimmune Inc |
Composiciones antagonistas del pd-1
|
US20110223188A1
(en)
|
2008-08-25 |
2011-09-15 |
Solomon Langermann |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
PT2344474E
(pt)
|
2008-09-02 |
2015-12-28 |
Novartis Ag |
Derivados de picolinamida como inibidores de cinase
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
WO2010028798A1
(fr)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Anticorps multivalents
|
WO2010030002A1
(fr)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
Cellule capable d'exprimer un ligand gitr exogène
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
DK2370076T3
(en)
|
2008-11-28 |
2017-04-03 |
Novartis Ag |
Pharmaceutical combination comprising an Hsp 90 inhibitor and an mTOR inhibitor
|
BRPI0917592B1
(pt)
|
2008-12-09 |
2021-08-17 |
Genentech, Inc |
Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
|
US20120029472A1
(en)
*
|
2008-12-19 |
2012-02-02 |
University Of Miami |
Tnfr25 agonists to enhance immune responses to vaccines
|
ES2550179T3
(es)
|
2009-02-05 |
2015-11-05 |
Icahn School Of Medicine At Mount Sinai |
Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
|
EP3192811A1
(fr)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Anticorps pd-1 et pd-l1 et leurs utilisations
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8703132B2
(en)
|
2009-06-18 |
2014-04-22 |
Hoffmann-La Roche, Inc. |
Bispecific, tetravalent antigen binding proteins
|
UA105794C2
(uk)
|
2009-06-26 |
2014-06-25 |
Новартіс Аг |
1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
|
AR077975A1
(es)
|
2009-08-28 |
2011-10-05 |
Irm Llc |
Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
|
KR20170119746A
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-gitr 항체
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
WO2011066342A2
(fr)
|
2009-11-24 |
2011-06-03 |
Amplimmune, Inc. |
Inhibition simultanée de pd-l1/pd-l2
|
SG10201501784YA
(en)
|
2009-12-07 |
2015-05-28 |
Univ Leland Stanford Junior |
Methods for enhancing anti-tumor antibody therapy
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
JP5856073B2
(ja)
|
2009-12-29 |
2016-02-09 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Ron結合構築体およびその使用方法
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
ES2638521T5
(es)
|
2010-03-05 |
2021-03-02 |
Univ Johns Hopkins |
Composiciones y métodos para anticuerpos y proteínas de fusión inmunomoduladores dirigidos contra dianas
|
PL2581113T3
(pl)
|
2010-06-11 |
2018-11-30 |
Kyowa Hakko Kirin Co., Ltd. |
Przeciwciało anty-tim-3
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
US20120014947A1
(en)
*
|
2010-07-16 |
2012-01-19 |
The University Of Chicago |
Methods and compositions to reduce liver damage associated with conditions or therapies that affect the immune system
|
BR112013004012B1
(pt)
|
2010-08-20 |
2021-03-23 |
Novartis Ag |
Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
|
ES2649155T3
(es)
|
2010-08-23 |
2018-01-10 |
Board Of Regents, The University Of Texas System |
Anticuerpos anti-OX40 y procedimientos de uso de los mismos
|
CA2807269A1
(fr)
|
2010-08-24 |
2012-03-01 |
Roche Glycart Ag |
Anticorps bispecifiques activables
|
WO2012025530A1
(fr)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Anticorps bispécifiques comprenant un fragment fv stabilisé par bisulfure
|
ES2579077T3
(es)
|
2010-09-21 |
2016-08-04 |
Altor Bioscience Corporation |
Moléculas de fusión solubles multímeras de IL-15 y métodos para elaborar y usar las mismas
|
CN107648668B
(zh)
|
2010-10-06 |
2021-06-18 |
哈佛学院董事会 |
用于基于材料的细胞疗法的可注射的成孔水凝胶
|
EP2655624B1
(fr)
|
2010-12-23 |
2017-11-29 |
Biogen MA Inc. |
Peptides coupleurs et polypeptides les comportant
|
ES2685327T3
(es)
|
2011-04-28 |
2018-10-08 |
President And Fellows Of Harvard College |
Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
|
WO2012158818A2
(fr)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
|
WO2012167230A1
(fr)
|
2011-06-03 |
2012-12-06 |
President And Fellows Of Harvard College |
Vaccin anticancéreux de génération d'antigène in situ
|
ES2894398T3
(es)
|
2011-06-03 |
2022-02-14 |
Xoma Technology Ltd |
Anticuerpos específicos para TGF-beta
|
EP3626739A1
(fr)
|
2011-06-24 |
2020-03-25 |
Stephen D. Gillies |
Protéines de fusion d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
WO2013043569A1
(fr)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Immunothérapie combinée à action antitumorale synergique faisant appel à des alloantigènes
|
US9382319B2
(en)
|
2011-09-26 |
2016-07-05 |
Jn Biosciences Llc |
Hybrid constant regions
|
WO2013049254A1
(fr)
|
2011-09-26 |
2013-04-04 |
Jn Biosciences Llc |
Régions constantes hybrides
|
KR102434073B1
(ko)
|
2011-10-11 |
2022-08-18 |
비엘라 바이오, 인크. |
Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
|
DK2785375T3
(da)
|
2011-11-28 |
2020-10-12 |
Merck Patent Gmbh |
Anti-pd-l1-antistoffer og anvendelser deraf
|
CN109125718A
(zh)
|
2012-01-13 |
2019-01-04 |
哈佛学院董事会 |
在结构聚合装置中tlr激动剂的控制传递
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
WO2013142255A2
(fr)
|
2012-03-22 |
2013-09-26 |
University Of Miami |
Agents de liaison multi-spécifiques
|
WO2013148228A1
(fr)
|
2012-03-29 |
2013-10-03 |
Advanced Cancer Therapeutics, Llc |
Inhibiteur de pfkfb3 et procédés d'utilisation en tant que produit thérapeutique anticancéreux
|
EP3662896B1
(fr)
|
2012-04-16 |
2024-02-28 |
President and Fellows of Harvard College |
Compositions de silice mésoporeuse pour moduler les réponses immunitaires
|
PL2838548T3
(pl)
|
2012-04-17 |
2024-02-05 |
University Of Washington Through Its Center For Commercialization |
Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania
|
PL2900637T3
(pl)
|
2012-05-15 |
2018-01-31 |
Novartis Ag |
Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns
|
PT2861579T
(pt)
|
2012-05-15 |
2018-04-27 |
Novartis Ag |
Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl
|
JP6078640B2
(ja)
|
2012-05-15 |
2017-02-08 |
ノバルティス アーゲー |
Abl1、abl2およびbcr−abl1の活性を阻害するためのベンズアミド誘導体
|
ES2665539T3
(es)
|
2012-05-15 |
2018-04-26 |
Novartis Ag |
Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CA2879814A1
(fr)
|
2012-08-02 |
2014-02-06 |
Jn Biosciences Llc |
Anticorps ou proteines de fusion multimerises par l'intermediaire de la mutation d'une cysteine et une piece de queue ?
|
TWI472974B
(zh)
|
2012-09-06 |
2015-02-11 |
Au Optronics Corp |
多類物體觸控點偵測方法
|
ES2747997T3
(es)
|
2012-10-24 |
2020-03-12 |
Novartis Ag |
Formas de IL-15R alfa, células que expresan formas de IL-15R alfa, y usos terapéuticos de IL-15R alfa y complejos IL-15/IL-15R alfa
|
BR112015010477A2
(pt)
|
2012-11-08 |
2017-07-11 |
Novartis Ag |
combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
|
WO2014085318A1
(fr)
|
2012-11-28 |
2014-06-05 |
Novartis Ag |
Polythérapie
|
EP3508215A3
(fr)
|
2012-12-03 |
2019-10-02 |
Bristol-Myers Squibb Company |
Amélioration de l'activité anticancéreuse de protéines de fusion fc immunomodulatrices
|
WO2014116846A2
(fr)
|
2013-01-23 |
2014-07-31 |
Abbvie, Inc. |
Procédés et compositions pour moduler une réponse immunitaire
|
CA2897682C
(fr)
|
2013-02-08 |
2023-03-14 |
Novartis Ag |
Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
MY180687A
(en)
|
2013-03-14 |
2020-12-07 |
Icahn School Med Mount Sinai |
Newcastle disease viruses and uses thereof
|
EP2970240B1
(fr)
|
2013-03-14 |
2018-01-10 |
Novartis AG |
3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
EP2970486B1
(fr)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation de cellules t avec des anticorps bispecifiques et des fusions fc
|
WO2014189806A1
(fr)
|
2013-05-18 |
2014-11-27 |
Aduro Biotech, Inc. |
Compositions et procédés d'inhibition de la signalisation dépendante du « stimulateur des gènes interférons »
|
JP6453855B2
(ja)
|
2013-05-18 |
2019-01-16 |
アドゥロ バイオテック,インク. |
「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
PE20161073A1
(es)
|
2013-11-01 |
2016-10-30 |
Novartis Ag |
Amino-heteroaril-benzamidas como inhibidores de cinasa
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
PT3116909T
(pt)
|
2014-03-14 |
2020-01-30 |
Novartis Ag |
Moléculas de anticorpos para lag-3 e suas utilizações
|
EP3151921B1
(fr)
|
2014-06-06 |
2019-08-28 |
Bristol-Myers Squibb Company |
Anticorps anti récepteur du facteur de nécrose tumorale induit par glucocorticoïdes (gitr) et leurs utilisations
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|